The U.S. Food and Drug Administration (FDA) approved a new, twice-yearly shot — the first and only of its kind — to prevent HIV, the creator of the drug, Gilead Sciences, announced on Wednesday.Sold under the name Yeztugo,

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

Yeztugo, a twice-a-year antiviral shot to prevent HIV, was approved by the Food and Drug Administration on Wednesday, marking a major advance in battling AIDS. The drug (which has the generic name lenacapavir) will become available in the U.S. following the approval, though it’s unclear who will initially have access to the drug.